Close

BIO Statement on USTR’s 2016 “Special 301 Report”

The Biotechnology Innovation Organization (BIO) released the following statement regarding The Office of the United States Trade Representative’s (USTR) 2016 Special 301 Report:

Presentation: "Global Health Challenges: How Industry is Addressing Global Health", presented at the University of Virginia in June 2008

Global Health Challenges: How Industry is Addressing Global Health

Eileen Yen, former Director, Sarawak Biodiversity Centre, Malaysia

Mark Rohrbaugh, Director, Office of Technology Transfer, National Institutes of Health (NIH)

Mark Rohrbaugh, Director, Office of Technology Transfer, National Institutes of Health (NIH), US Department of Health & Human Services, USA

Ted Roumel, Vice President for Research Innovation & Commercialization at the University of Maryland Biotechnology Institute, USA

Innovation And The Global Research Enterprise WORLD HEALTH ORGANIZATION GENEVA—NOVEMBER 2007 THEODORE J. ROUMEL VICE PRESIDENT for RESEARCH, INNOVATION AND COMMERCIALIZATION UNIVERSITY OF MARYLAND BIOTECHNOLOGY INSTITUTE

Diran Makinde, Network Director, NEPAD Biosciences, West Africa Biosciences Network (WABNet), Senegal

Government's role in developing solutions for diseases that disproportionately affect developing countries

BIO 2016 Special 301 Submission

The Biotechnology Innovation Organization (BIO) appreciates the opportunity to comment on the 2016 Special 301 Submission. 

BIO President and CEO Jim Greenwood to Chair BIO Ventures for Global Health Board of Directors

BVGH engages leading biopharmaceutical companies in partnerships and programs to address challenging global health issues

BIO Comments on Draft Patents (Amendment) Rule 2015

The Biotechnology Industry Organization (BIO) greatly appreciates the opportunity to provide comments/suggestions of the stakeholders on the Draft Patents (Amendment) Rules 2015 published by the Ministry of Commerce & Industry.

BIO Joins Coalition Cautioning Against Further Restructuring of Japan’s Pharmaceutical Pricing Structure

Today BIO joined a coalition of organizations urging the Government of Japan to maintain the established reimbursement pricing structure for pharmaceuticals and medical devices.